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Abstract
The hope of success of therapeutic interventions largely relies on the possibility to distinguish between even close tumor
types with high accuracy. Indeed, in the last ten years a major challenge to predict the responsiveness to a given
therapeutic plan has been the identification of tumor specific signatures, with the aim to reduce the frequency of unwanted
side effects on oncologic patients not responding to therapy. Here, we developed an in vitro evolution-based approach,
named differential whole cell SELEX, to generate a panel of high affinity nucleic acid ligands for cell surface epitopes. The
ligands, named aptamers, were obtained through the iterative evolution of a random pool of sequences using as target
human U87MG glioma cells. The selection was designed so as to distinguish U87MG from the less malignant cell line T98G.
We isolated molecules that generate unique binding patterns sufficient to unequivocally identify any of the tested human
glioma cell lines analyzed and to distinguish high from low or non-tumorigenic cell lines. Five of such aptamers act as
inhibitors of specific intracellular pathways thus indicating that the putative target might be important surface signaling
molecules. Differential whole cell SELEX reveals an exciting strategy widely applicable to cancer cells that permits
generation of highly specific ligands for cancer biomarkers.
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Introduction
A major challenge in oncology aims at the characterization of
the heterogeneity of disease by defining more reliable diagnostic/
prognostic factors and at developing effective anticancer thera-
peutics selectively targeting tumor cells. Indeed, cancer is a
complex disease characterized by the accumulation of several and
often unknown molecular alterations that cause genetic instability,
cell proliferation, and acquisition of an increasingly invasive phe-
notype resistant to therapeutic treatments. In turn the heteroge-
neity of malignant cells combined to the variability of the patient’s
genetic background create different cancer phenotypes with
distinct clinical outcomes. By reducing the degree of uncertainty
on the clinical status of individual patients, the simultaneous
analysis of multiple biomarkers improves the possibility to
distinguish between two even close tumor types and predict
distinct therapeutic responses.
Aptamers are small and highly structured single-stranded oligonu-
cleotides that bind at high affinity (within the low nanomolar range) to
a target molecule by providing a limited number of specific contact
points imbedded in a larger, defined three-dimensional structure
[1,2,3,4,5].
Aptamers are isolated by the Systematic Evolution of Ligands
by EXponential enrichment (SELEX) technology and since from
their first description in 1990 [1,6], aptamers soon became a
valuable research tool and show great application prospected in
fundamental research, drug selection and clinical diagnosis and
therapy. At present, aptamers against many kinds of proteins have
come into clinical test phase [7,8,9].
Recently, nucleic acid aptamers have been selected against
whole living cells, with the advantage of a direct selection of
ligands without prior knowledge of the target molecules, notably
by using as target red blood cells [10], leukemia cells [11] small
lung cancer cells [12] and rat brain tumor microvessels [13].
Nonetheless, the use of complex cells as targets has been shown to
enable the identification of aptamers that bind large cell surface-
specific markers, in their native conformation.
Indeed, by applying SELEX technology against whole-living
cells in culture, for the first time we succeeded in demonstrating
that even by using complex targets as intact cells, it is possible to
obtain aptamers against even rare antigens if specifically expressed
on the target cell [14]. We adopted this strategy to generate
nuclease resistant RNA-aptamers specific for PC12 cells expressing
the human receptor tyrosine kinase, Ret and selected aptamers
that bind specifically to Ret and inhibit its downstream signaling
effects [14].
Herein, we have developed a whole-cell SELEX protocol with
the aim to generate aptamers able to discriminate within the same
tumor between two strictly related phenotypes. We used
glioblastoma cell lines as model system because of the complex
cellular heterogeneity of malignant gliomas and the need to find
new diagnostic and therapeutic modalities for these tumors. By
using a counterselection/selection approach, specifically designed
to enrich for aptamers against cell surface tumor-specific targets,
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7971we have generated a panel of RNA-aptamers able to bind at high
affinity to malignant U87MG cells. They do not bind the non
tumorigenic T98G nor other non-related cancer cell types, but
bind to glioma cell lines characterized by different malignant
phenotypes at different extents. Furthermore, functional analysis
revealed that some of the aptamers inhibit specific intracellular
signaling pathways.
Our results indicate the differential whole-cell SELEX strategy
as a promising strategy to develop specific molecular probes for
early diagnosis and prediction of aggressiveness and therapeutic
response that is generally applicable to different strictly related
cell types.
Results
Enrichment of Selection for a Complex Target
In order to isolate cell specific ligands for a given tumor cell
phenotype we decided to keep as model system stable human
glioma cell lines. Even though using stable cell lines has the
drawback of skipping epitopes that might be important for the in
vivo cell growth, it has the obvious advantage to handle a cell
population under well controlled growth conditions that remain
stable all along the SELEX procedure. We used as target for the
selection steps the malignant human U87MG glioma cell line and
for the counterselection steps less malignant human T98G glioma
cells. These two cell lines differ for the potential to form tumors in
nude mice, U87MG being highly tumorigenic while the T98G are
poorly tumorigenic. On the other hand, these cell lines share same
cellular pathways altered, both harboring p14
arf/p16 deletion and
phosphatase and tensin homolog (PTEN) mutation. Major
differences found between the two cell lines are the levels of
ErbB2 and of phosphorylated extracellular signal-regulated
protein kinase (ERK), that are higher in U87MG than in T98G,
while phosphorylated Akt and neural cell adhesion molecule
(NCAM) levels were similar (data not shown). The relative levels of
these four molecules were monitored at each cycle of the SELEX
procedure to verify and standardize the growth conditions of
the cells.
A library of 2’Fluoro Pyrimidines (2’F-Py), nuclease-resistant
RNAs was utilized for differential SELEX against intact cells
(Fig. 1). At each round the selection step on U87MG cells was
preceded by one or two counterselection steps against T98G cells.
During the selection process, we progressively increased the
selective pressure by changing both incubation and washing
conditions. During rounds 13 and 14, restriction fragment length
polymorphism analysis (RFLP) profiles remain unchanged,
suggesting that the population had stopped to evolve under the
selection pressure (data not shown). Indeed, as assessed by
comparing the in vitro binding efficiency on the two cell lines and
to the naı ¨ve starting pool (not shown), after 14 rounds of selection,
the pool, named G14, was enriched for aptamers that preferen-
tially bind to U87MG cells.
Distribution of Individual Sequences
In order to isolate individual aptamers that may distinguish the
more malignant U87MG phenotype, a panel of 71 sequences was
cloned from the pool G14, and aptamers grouped in families based
on their primary sequence similarity (Fig. 2). We identified ten
families of highly related aptamers that together cover more than
46% (33 aptamers) of all individual sequences obtained from the
selection; one single individual sequence dominated the selection
and constituted 8% of all the clones; five other sequences
Figure 1. Selection of U87MG cell-specific aptamers. A pool of 2’F-Py RNAs was incubated with poorly tumorigenic T98G cells
(Counterselection). Unbound sequences in the supernatant were recovered and incubated with tumorigenic U87MG cells for the selection step
(Selection). Unbound sequences were discarded by washings and bound sequences were recovered by total RNA extraction. Sequences enriched by
the selection step were amplified by RT-PCR and in vitro transcription before a new cycle of selection.
doi:10.1371/journal.pone.0007971.g001
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PLoS ONE | www.plosone.org 2 November 2009 | Volume 4 | Issue 11 | e7971Figure 2. Analysis of individual sequences similarity. Dendogram (obtained by using DNASIS software version 2.1) for visual classification of
similarity among 71 individual sequences cloned after 14 rounds of selection. Aptamers are grouped in 10 families of sequences found more than
once (labeled with the asterisk) or that share sequence similarity (boxed).
doi:10.1371/journal.pone.0007971.g002
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38 sequences were poorly related to each other (Fig. 2).
We thus screened for those aptamers that efficiently target the
U87MG cells. To this aim a panel of 21 individual aptamers,
including at least one member for each family, was analysed for
binding at the concentration of 500 nM. At that concentration, 8
aptamers display up to five-fold increase of binding to U87MG
cells with respect to the starting pool, while the remaining 13
aptamers show no specific binding to U87MG (not shown). Using
the starting pool as control of background, the binding affinity of
individual aptamers to U87MG cells and T98G cells was then
determined. As shown in Table 1, all 8 sequences (GL17, GL56,
GL62, GL36, GL35, GL43 GL44 and GL21) bind at high affinity
(with Kd ranging between 33 nM and 700 nM) to the U87MG
cells and have no or low affinity for T98G (not shown). Michaelis-
Menten binding curves of three aptamers are shown in Fig. 3A.
Given the good specificity and high affinity for the U87MG cells
we restricted our further analysis of biochemical and biological
properties to these 8 sequences.
Comparison of Individual Sequences
Four of the eight aptamers considered (GL21, GL17, GL56 and
GL62) have unrelated primary sequences and predicted 2D folded
structures. Two (GL44 and GL43) differ for the presence of two
cytosines (cyt42 and cyt43) that are only present in GL44 whose
presence however does not alter the affinity for the target cells (see
Table 1). Comparing the predicted secondary structures defined a
conserved stem-loop (residues 1–39) presents with an identical
sequence in both aptamers (Fig. 3B). Consistently the shortened
sequence, constituted of the first shared 39 residues (herein named
GL44-43 short), is sufficient to bind to the U87MG cells displaying
a Kd of 30 nM (Fig. 3C) and discriminate them from T98G cells
(not shown). The opposite situation was found in another couple of
aptamers (GL35 and GL36) that even if poorly differ in their
primary structures, have binding affinities that differ of around 4
times (Table 1).
Binding Specificity
The identification of a small set of aptamers that may
distinguish the U87MG cells from the T98G cells raises the
obvious question of whether these aptamers may bind as well other
cell types. To this aim we determined the relative binding potential
of each aptamer to several cell lines. We first determined the cell
type specificity by measuring at the same concentration of 50 nM
the binding of each aptamer on a panel of unrelated cell lines. We
found that any of the eight aptamers did not bind to other human
cancer cell types analyzed including neuroblastoma (SK-N-BE and
SH-SY5Y), lung (H460 and Calu1) and breast (MCF7 and
SKBR3) cancer cells nor to murine fibroblast NIH3T3 cells, as
assessed by comparison with the unspecific binding of the starting
pool, G0 data not shown). On the other hand, even if at different
extents they bind to various glioma cell lines (U251MG, TB10,
LN-18 and LN-229) and a U87MG derivative, U87MGDEGFR,
but not the T98G cells used for counterselection. These cell lines
are characterized by different tumor type derivation and
malignant phenotypes and have different genetic backgrounds.
As shown in Fig. 4A, at that concentration each aptamer has
a distinct pattern of binding on different glioma cell lines (see
Legend). At these experimental conditions, all aptamers have good
binding with the highly tumorigenic cell lines (U87MG, LN-229,
U87MGDEGFR and TB10), the aptamers GL56 binds to all cell
lines except to the non tumorigenic T98G, and GL17 binds only
the four highly tumorigenic cell lines. Thus the pattern of binding
of five of these aptamers (for example, GL44, GL17, GL56, GL36
and GL35) is sufficient to distinguish two cell lines. Further we
confirmed that aptamers can distinguish tumorigenic from non
tumorigenic glioma cells by determining binding of four of them
(GL21, GL35, GL36 and GL44-43 short) to highly tumorigenic
cell lines (U87MG, Gli36, and Gli36DEGFR) as compared to two
cell lines (A172 and T98G) that are unable to form tumors in nude
mice (Fig. 4B). Furthermore, the eight aptamers bind also to
primary cell cultures of malignant glioblastomas and discriminate
them from a not-related meningeoma cell line, thus excluding the
recognition of possible unwanted epitopes enriched upon immor-
talization of a stabilized cell line (Fig. 4C). For each aptamer the
differences observed in the extent of binding likely reflect the
relative concentrations of the same target molecules in the different
cell lines.
Biological Activities of Aptamers
As previously demonstrated for the anti Ret receptor tyrosine
kinase D4 aptamer, high affinity aptamer binding to an
extracellular receptor may inhibit activity of key downstream
transducing molecules, such as ERK family members. Therefore,
we first determined whether treating the U87MG cells with any of
these aptamers may affect the phosphorylation of either Akt and
ERK 1/2.
Table 1. Sequence of indicated aptamers; for simplicity fixed-primer sequences at 59 and 39 are not shown.
Binding affinity of individual aptamers to U87MG cells
Name Sequence Kd (nM)
GL17 CCGUUGUUCUACAUGUCACUCAUCACGCGAGUCUUUUGUCUAA 102612
GL21 GCCUCUCAACGAUUAAUGUUUCGUUAACAUGAUCAAUCGCCUCAA 221625
GL62 UUCACACACUCAAUUGAACGGUGAUUCAAGUUAUUAGCAGCCUCA 710640
GL43 ACGUUACUCUUGCAACAC- --AAACUUUAAUAGCCUCUUAUAGUUC 4464
GL44 ACGUUACUCUUGCAACACC CCAAACUUUAAUAGCCUCUUAUAGUUC 3863
GL56 UGAUUUUGCAGCACUUCUUGUUAUCUUAACGAACUGUUGAUGA 6369
GL36 UACCAAACGCGCA AAUUUUCA AUCUU UGUAAUAACCAAAUGCCUCUGA 190620
GL35 UACCAAACGCGCG GGUUUUCG GUCUC CGUAAUAACCAAAUGCCUCUGA 4467
Residues that differ among the sequences in the couple (GL43 and GL44) or (GL36 and GL35) are in bold.
Michaelis-Menten binding curves to estimate Kd (nM) were performed as described in Materials and Methods; standard deviation values were determined from at least
four independent experiments.
doi:10.1371/journal.pone.0007971.t001
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and GL21) at 200 nM inhibited ERK phosphorylation of at
least two-fold, as compared to the control starting pool and to
the other aptamers (GL17, GL56, GL62) (not shown). On the
other hand, no aptamer had any relevant effect on the phos-
phorylation of Akt and of the 3-Phosphoinositide-dependent
protein kinase-1 (PDK1) (not shown), most likely because the
U87MG harbor a mutated inactive phosphatase and tensin
homolog (PTEN), a phosphatase that dephosphorylates the
phosphatidylinositol (3,4,5)-trisphosphate, thus resulting in inhi-
bition of the Akt signaling pathway [15].
To further confirm the biological activity of GL36, GL35,
GL44, GL43 and GL21, we determined the extent of inhibition of
expression of the cell cycle-related protein, cyclin D1 and of
phosphorylation of ERK 1/2 upon treatment of U87MG cells
with aptamers for increasing time periods.
The cyclin D1 proto-oncogene is an important regulator of G1
to S-phase transition, causing downregulation of protein levels
through its protein expression and through phosphorylation-
dependent degradation, and causing inhibition of cell cycle
progression by inducing a G1 arrest [16,17]. We thus performed
time-course experiments with the five inhibitor aptamers looking
at its protein expression and phosphorylation levels. As shown in
Fig. 5A, treatment with cognate aptamers either GL36 and GL35,
or GL44 and GL43, inhibits at similar extents basal cyclin D1
expression and phosphorylation in a time dependent manner.
Further, treating cells with the aptamer GL21 resulted as well in a
stronger and more rapid inhibition of cyclin D1 reaching around
26% at 1 h.
As shown in Fig. 5B treatment with the same five aptamers
caused a similar time dependent inhibition of ERK phosphory-
lation, inhibition being more rapid with GL35 than GL36, thus
according to their respective Kd values (see Table 1), and, as
expected, at comparable extents treating with the highly related
GL44 and GL43 aptamers. In agreement with its Kd value, the
GL44-43 short aptamer, inhibited cyclin D1 expression and ERK
phosphorylation at a similar extent of the GL44 aptamer (not
shown). To further demonstrate the biological activity of these
aptamers we treated growing U87MG cells with either GL44-43
short or the GL21 aptamer and monitored the inhibitory effect on
cell proliferation by pulse labeling thymidine incorporation.
According with inhibition of ERK activity, treating cells with
aptamers for 24 and 48 hs strongly reduces [
3H]thymidine
incorporation (Fig. 5C).
Figure 3. Dissociation constants of GL35, GL36, GL21 and GL44-43 short aptamers. (A) Binding curve of GL35, GL36 and GL21 aptamers on
U87MG. Lineweaver-Burk analysis (inset) was used for the evaluation of the binding constant (see Materials and Methods). (B) Secondary structure of
a shortened sequence consisting of residues 1–39 of GL44 or GL43 aptamers (GL44-43 short). predicted by using MFOLD software version 3.1
(available at http://www.bioinfo.rpi.edu/applications/mfold/). (C) Binding curve of the GL44-43 short aptamer on U87MG cells.
doi:10.1371/journal.pone.0007971.g003
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PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7971Figure 4. Binding analyses of the best sequences to glioma cell lines. The indicated aptamers or the starting pool (G0) were 59-[
32P]-labeled
and incubated in the same condition at 50 nM with the indicated stable glioma cell lines (A and B) or primary cultures of malignant glioma cells (C).
The results are expressed relative to the background binding detected with the starting pool. In (A) and (B) the tumorigenic potential in nude mice is
indicated on the basis of the time of appearance of tumor and the tumor growth rate as previously reported [15,23,31,32]: high tumorigenicity is
indicated as ‘‘++’’; middle tumorigenicity is indicated as ‘‘+’’ and no tumorigenicity is indicated as ‘‘-’’. In (A), the binding capacity of the aptamers to
the cells is reported: high binding (more than four-fold) is indicated as ‘‘++’’, middle binding (between two and four-fold) is indicated as ‘‘+’’ and no
binding (less than two-fold) is indicated as ‘‘-’’.
doi:10.1371/journal.pone.0007971.g004
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PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7971Figure 5. Biological activities of selected aptamers. Serum starved U87MG cells were either left untreated or treated with 200 nM of the
indicated RNA aptamers or G0 for the indicated incubation times. (A) Cell lysates were immunoblotted with anti-phosphocyclin D1 and cyclin D1
antibodies. To confirm equal loading the filters were stripped and reprobed with anti-a-tubulin antibodies. (B) Cell lysates were immunoblotted with
anti-phosphoERK antibodies and the filters were stripped and re-probed with anti-ERK antibodies. In (A) and (B), intensity of bands has been
calculated using the NIH-Image Program on at least two different exposures to assure the linearity of each acquisition. Four independent experiments
were performed. Fold values are expressed relative to the reference points, arbitrarily set to 1 (labeled with asterisk, lane 1). ‘‘C’’ indicates mock-
treated cells. Plots of fold values corresponding to the cyclin D1 expression and to ERK activity are reported for each lane of immunoblotting shown
in (A) and in (B), respectively. (C) U87MG cells were treated for 24 hs or 48 hs with the indicated aptamers or the G0 starting pool and proliferation
was determined by [
3H]-thymidine incorporation. In (A), (B) and (C), vertical bars indicate the standard deviation values.
doi:10.1371/journal.pone.0007971.g005
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PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7971Taken together the results indicate that these five aptamers
harbor intrinsic biological activity and may act as inhibitory
ligands of critical cell surface molecules.
Discussion
Cancer cell surface epitopes that may discriminate a specific cell
phenotype whilst embedded in a heterogeneous cell population are
highly promising targets for developing personalized innovative
therapeutics. Human gliomas are highly heterogeneous tumors
whose sensitivity to therapeutic approaches is hard to predict.
Several glioma derived cell lines have been shown to differ in the
pattern of expression of receptor tyrosine kinases and in their
involvement in cell proliferation [18], thus gliomas may constitute a
model of choice in which to demonstrate the possibility to obtain a
panel of aptamers that may distinguish a given glioma phenotype.
Here we adopted a differential SELEX protocol to target whole
living human glioma derived cells, the U87MG cell line, and we
obtained a panel of nuclease-resistant RNA ligands capable of
binding at high affinity to the surface of target cells and to
distinguish them from other glioma cell lines.
Furthermore, because of the importance of several membrane
bound proteins as regulators of cancer cell proliferation we
determined in U87MG cells whether any of such aptamers may
interfere with the transmission of intracellular signaling and
demonstrated that five of these molecules inhibited the activity of
critical molecules in cell proliferation, ERK 1/2 and cyclin D1,
but not Akt. Lack of inhibition of Akt likely rely on the fact that
these cells bear an inactive PTEN, a negative regulator of Akt, and
thus the levels of Akt phosphorylation are only poorly regulated by
extracellular stimuli [15].
The use of living cells as targets for SELEX has been already
described by us and by others [19]. Indeed, we have already
demonstrated that it is possible to obtain aptamers for a given
transmembrane receptor tyrosine kinase if an appropriate protocol
is adopted thus providing the first evidence of the possibility to use
SELEX to distinguish between cells that differ for a single (or few)
membrane epitope [14,20].
Here we adopted a similar approach to distinguish between
closely related tumor cell lines by targeting unknown epitopes on
the cell surface. To surmount the possible drawback of obtaining
aptamers targeting few highly represented epitopes we monitored
the evolution process by RFLP and stopped the SELEX rounds as
soon as the enrichment of the library was visible, i.e. at round 14.
This strategy allowed us to obtain aptamers against multiple
surface epitopes with Kd values in the nanomolar range, a further
increase in affinity is expected by applying further SELEX rounds
to each individual aptamers (work in progress). As a first attempt to
identify those aptamers that better discriminate the U87MG cells,
we screened 21 individual aptamers for their binding at 500 nM to
U87MG cells over the naı ¨ve G0 random pool. Even if we
identified eight aptamers that specifically bind cells at that
concentration, given that in this assay we used an unique aptamers
concentration we cannot conclude on the specificity of the binding
properties of the remaining thirteen aptamers on either U87MG
or T98G cells.
Our strategy allowed us to obtain eight, of which six are
unrelated, aptamers that bind bona fide distinct epitopes present on
the cell surface. Further, by this approach we generated a panel of
ligands that bind cells used for selection but neither those used for
counterselection nor unrelated cancer cells, from neuroblastoma,
breast, and lung cancer cell lines. Most importantly, by combining
their pattern of binding allows to identify a given glioma cell line
among the seven analyzed. Further, the differences in binding are
not randomly distributed but in contrast they fit well with
important growth properties of each cell line, as tumorigenicity in
nude mice, thus suggesting that the extent of binding of an
aptamer (see for example GL17) may associate with at least one
biological property.
We measured binding efficiency on each cell line using the same
concentration of 50 nM for all aptamers. This strategy even if it
doesn’t exactly reflect the differences in Kd between aptamers
(calculated on the U87MG cells) revealed as a simple and direct
way to obtain a specific pattern of binding for each cell line. As
expected the two cell lines used for selection and counterselection
have the best and worst binding for all the aptamers, respectively.
Aptamers have been shown to frequently inhibit the function of
their target molecules, presumably by interfering with binding of
the cognate ligand [21]. As mentioned above the strategy adopted
should allow to enrich for aptamers that target molecules even
present at low abundance on the cell surface as for example
receptors and other transducing molecules, as already shown for
ligands to the receptor tyrosine kinase Ret [14]. The effectiveness
of the strategy adopted is well highlighted by the fact that out of
eight aptamers that bind to the U87MG, five interfere with the
activity of critical molecules for intracellular signaling and cell
proliferation likely binding to and/or inhibiting a membrane
bound receptor in its active conformation.
In conclusion, we developed a differential SELEX-based
procedure that allowed us to generate a highly informative panel
of few specific and selective aptamers for malignant glioma cells.
The identification of cellular targets for each of these aptamers is
in progress. Major advantages of SELEX are the relative rapidity
of the entire process and to be only based on artificial molecules.
Therefore, the concrete prospective that by such a procedure it is
possible to identify and validate important surface target molecules
will certainly reveal this as a rather unique tool to discover new
molecular targets for antibodies or short peptides.
Materials and Methods
Ethics Statement
Primary tumor cultures were derived from surgical biopsies.
The study protocol was approved by the local Ethics Committee of
the University of Cologne. Written informed consent was acquired
prior to surgery from every patient for further studies on primary
glioma cultures.
Cell Culture and Immunoblotting
Human glioma U87MG (American Type Culture Collection,
ATCC no. HTB-14), T98G (ATCC no. CRL-1690), A172
(ATCC no. CRL-1620), U251MG (kindly provided by A.
Porcellini), TB10 (kindly provided by A. Porcellini), Gli36 [22]
cells were grown in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 2 mM L-glutamine, 10% fetal bovine serum
(Invitrogen, Carlsbad, CA). Human glioma, LN-18 (ATCC
no. CRL-2610), LN-229 (ATCC no. CRL-2611) were grown in
Advanced DMEM supplemented with 2 mM L-glutamine, 10%
fetal bovine serum (Invitrogen, Carlsbad, CA). U87MGDEGFR
and Gli36DEGFR, expressing a truncated mutant EGFR receptor
due to an in-frame deletion of exons 2–7 from the extracellular
domain (DEGFR) [23], were grown in DMEM supplemented with
2 mM L-glutamine, 10% fetal bovine serum, 500 mg/ml genta-
mycin (Invitrogen, Carlsbad, CA). Growth conditions for cell lines
used were previously reported: human neuroblastoma SH-SY5Y
and SK-N-BE cells [24], human breast MCF7 and SKBR3 cells
[25], human NSCLC H460 and Calu1 cells [26] and NIH3T3
cells [14].
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brain tumors were derived as described previously [27]. Each tumor
specimen was cut into small pieces, removing blood vessels, then
resuspended in trypsin solution (4% in 0.01 M PBS, pH 7.2). After
incubation (37uC, 10 min), DMEM (Life Technologies, Karlsruhe,
Germany) supplemented with 20% FBS (Roche Diagnostics,
Mannheim, Germany), 100 U/ml penicillin, 100 mg/ml strepto-
mycin (P/S; Life Technologies) and 1% amphotericin (SIGMA,
Steinheim, Germany) was added and the cell suspension was
centrifuged (210 rcf, 6 min). The pellet was resuspended in DMEM
with 20% FBS, 1% P/S and 1% amphotericin and grown at 37uC
in a 5% CO2/95% air atmosphere. When primary tumor cell
cultures formed nearly confluent monolayers, they were frozen and
stored in liquid nitrogen for further use.
To assess the functional effects of aptamers, U87MG (300 000
cells per 3.5-cm plate) were serum starved for 2 hs and then
treated with the RNA aptamers or the starting RNA G0 pool prior
subjected to a short denaturation-renaturation step. Cell extracts
preparation and immunoblotting analysis were performed as
described [28]. The primary antibodies used were: anti-ERK1
(C-16) (Santa Cruz Biotechnology, Santa Cruz, California, United
States) and anti-phospho-44/42 MAP kinase (indicated as anti-
pErk), anti-Akt, anti-phospho-Akt (Ser473, indicated as anti-pAkt),
anti-PDK1,anti-phospho-PDK1(Ser241,indicatedasanti-pPDK1),
anti-phospho-cyclin D1 (Thr286, indicated as anti-pcyclin D1) and
anti-cyclin D1 (all from Cell Signaling, Beverly, MA), anti-a-tubulin
(DM 1A) (Sigma, St. Louis, MO).
Whole-Cell SELEX
The SELEX cycle was performed essentially as described
[29]. Transcription was performed in the presence of 1 mM 29-F
pyrimidines and a mutant form of T7 RNA polymerase (2.5 u/ml
T7 R&DNA polymerase, Epicentre Biotechnologies, Madison,
WI.) was used to improve yields. 2’F-Py RNAs were used because
of their increased resistance to degradation by seric nucleases. 2’F-
Py RNAs (800-300 pmol) were heated at 85uC for 5 min in 1.5 ml
of DMEM serum free, snap-cooled on ice for 2 min, and allowed
to warm up to 37uC. Before incubation with the cells, 13.5 ml of
medium were added to RNA to reach a final volume of 15 ml.
Counterselection against T98G cells. To avoid selecting for
aptamers non-specifically recognizing the U87MG cell surface, the
pool was first incubated for 30 min (up to round 9) or for 15 min
(for the following rounds) at 37uC with 10
7 T98G cells (150-mm
cell plate), and unbound sequences were recovered for the
selection phase. This step was meant to select sequences
recognizing specifically the U87MG cells.
Selection against U87MG cells. The recovered sequences were
incubated with 10
7 U87MG cells for 30 min at 37uC and
recovered after several washings with 5 ml of DMEM serum free
by total RNA extraction (Ambion, Austin, TX).
During the selection process, we progressively increased the
selective pressure by increasing the number of washings (from one
for the first cycle up to five for the last cycles) and by decreasing
the incubation time (from 30 to 15 min from round 9). To follow
the evolution of the pool we monitored the appearance of four-
base restriction sites in the population by RFLP as previously
described [30].
Binding Analysis
Binding of individual aptamers (or the starting pool as a control)
to glioma cells was performed in 24-well plates in triplicate with 59-
[
32P]-labeled RNA. 3.5610
4 cells per well were incubated with
various concentrations of individual aptamers in 200 ml of DMEM
serum free for 20 min at RT in the presence of 100 mg/ml
polyinosine as a nonspecific competitor (Sigma, St. Louis, MO).
After five washings of 500 ml DMEM, bound sequences were
recovered in 300 ml of SDS 1%, and the amount of radioactivity
recovered was counted. The background values obtained with the
starting pool were subtracted from the values obtained with the
specific aptamers. Apparent Kd values for each aptamer were
determined by Lineweaver-Burk analysis according to the
equation:
1= complex ½  ~ Kd= Cmax ½  x1 = aptamer ½  z 1= Cmax ½  :
[
3H]-Thymidine Incorporation Assay
U87MG cells were plated in 24-well dishes (2610
4 cells/well)
and treated for 24 hs or 48 hs with aptamer (as indicated) or the
starting pool (G0) as control. During the final 4 hs, cells were
pulsed with 1 mCi/ml [
3H]-thymidine (45 Ci/mmol) (Amersham-
Pharmacia Biosciences) added in complete growth medium and
incubated at 37uC. At the end of each pulse, cells were harvested
and [
3H]-thymidine incorporation was analyzed by a Beckman LS
1701 Liquid Scintillation Counter.
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